Dyadic International Inc (DYAI)

NASDAQ
5.410
+0.040(+0.74%)
After Hours
5.410
0.000(0.00%)
- Real-time Data
  • Volume:
    412,695
  • Bid/Ask:
    5.150/5.410
  • Day's Range:
    5.180 - 5.649
  • Type:Equity
  • Market:United States
  • ISIN:US26745T1016
  • CUSIP:00026745T101

DYAI Overview

Prev. Close
5.37
Day's Range
5.18-5.649
Revenue
2.17M
Open
5.27
52 wk Range
3.15-8.63
EPS
-0.42
Volume
412,695
Market Cap
151.91M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,896,057
P/E Ratio
-
Beta
0.1
1-Year Change
-32.88%
Shares Outstanding
28,079,157
Next Earnings Date
Nov 11, 2021
What is your sentiment on Dyadic International Inc?
or
Market is currently closed. Voting is open during market hours.

Dyadic International Inc News

Dyadic International Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralBuyStrong Buy
Technical IndicatorsStrong BuyBuyBuyStrong SellSell
SummaryStrong BuyBuyNeutralNeutralNeutral

Dyadic International Inc Company Profile

Dyadic International Inc Company Profile

Employees
6

Dyadic International, Inc. is a global biotechnology company. The Company is focused on developing and licensing the C1 platform for use in human and animal pharmaceutical applications across the world. The Company has developed a method for producing commercial quantities of enzymes and other proteins, which it uses to develop and produce some of its own industrial enzymes, as well as licensing this technology to third parties. This technology is based on the Myceliopthora thermophila fungus, which the Company named C1. The C1 technology is a fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.

Read More
  • do we know what's going on Jesus why this drop
    1
    • we jus broke resistance @5.62 why we any one be selling seriously this could easily go to 8 by this week but we need to hold next resistance is @ 6.55
      1
      • this will fly by Monday
        1
        • Dyadic International (NASDAQ:DYAI) soars 22% premarket after signing a binding term sheet to enter into a License Agreement with Sorrento Therapeutics (NASDAQ:SRNE) to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100, produced using DYAI's proprietary and patented C1-cell protein production platform.“The license agreement, when executed, contemplates an up-front payment of $10 million in cash and stock, up to $4 million in reimbursements for preclinical and clinical development costs incurred by Dyadic for the development and advancement of our proprietary DYAI-100 vaccine, up to $33 million in milestone payments and ongoing royalties following commercialization. All future development costs related to this license will be incurred by Sorrento,” said Mark Emalfarb, Dyadic’s President and CEO.Upon execution, Sorrento will obtain exclusive rights in North and South America, Europe, major
          0
          • if they can make it :D
            0
        • DYAI $3.40 -12.60% @ Close!
          0
          • I'm thinking by March 9th, this ones gonna be jumpin.
            1
            • Jumped into June; then 💤😴
              0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.